SCHEMBL9944211

SCHEMBL9944211

CCOc1c(F)cc(C(=O)Nc2ccc(C(C)=O)cc2)cc1F

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.53
KDM4E B2RXH2 1/20 0.53
ALDH1A1 P00352 1/20 0.53
CYP1A2 P05177 1/20 0.53
SMN1; SMN2 Q16637 5/20 0.52
RAB9A P51151 3/20 0.52
TP53 P04637 2/20 0.52
KMT2A Q03164 8/20 0.52
MEN1 O00255 5/20 0.52
GAA P10253 2/20 0.52
MAPT P10636 4/20 0.51
KCNQ3 O43525 1/20 0.51
KCNQ2 O43526 1/20 0.51
POLB P06746 2/20 0.50
LMNA P02545 1/20 0.49
SNCA P37840 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1458437 0.89 MITF (0.57) NPC1KDM4EALDH1A1CYP1A2SMN1; SMN2
SCHEMBL9944324 0.84 GAA (0.50) NPC1KDM4EALDH1A1CYP1A2SMN1; SMN2
SCHEMBL9944170 0.84 KMT2A (0.64) NPC1KDM4EALDH1A1CYP1A2SMN1; SMN2
SCHEMBL9944195 0.84 MAPT (0.62) NPC1KDM4EALDH1A1CYP1A2SMN1; SMN2
SCHEMBL1457728 0.81 MEN1 (0.54) NPC1KDM4EALDH1A1CYP1A2SMN1; SMN2
SCHEMBL9944181 0.80 SMN1; SMN2 (0.62) NPC1KDM4EALDH1A1CYP1A2SMN1; SMN2
SCHEMBL9944194 0.80 KMT2A (0.56) NPC1KDM4EALDH1A1CYP1A2SMN1; SMN2
SCHEMBL9944240 0.78 MAPT (0.58) NPC1KDM4EALDH1A1CYP1A2SMN1; SMN2
SCHEMBL9944219 0.78 TAS1R3 (0.55) NPC1KDM4EALDH1A1CYP1A2SMN1; SMN2
SCHEMBL5973851 0.77 NPC1 (0.65) NPC1KDM4ESMN1; SMN2RAB9ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG NPC1 277/4885KDM4E 2548/4885ALDH1A1 128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.